Phase II Study on Neoadjuvant Therapy of AK104 Combined With Nab-paclitaxel/Carboplatin in Fertility Preserving Surgery

This study tests whether giving immunotherapy (AK104) plus chemotherapy before surgery can shrink cervical cancer tumors enough to allow fertility-preserving surgery (keeping the uterus) instead of a full hysterectomy. It targets young women with locally advanced cervical cancer who wish to have children in the future. **You may be eligible if...** - You are between 18 and 45 years old - You have confirmed stage IB2 or IB3 cervical cancer (squamous cell, adenocarcinoma, or adenosquamous) - Your cancer has not spread beyond the cervix and there are no distant metastases - You have not received any prior cancer treatment - You wish to preserve fertility **You may NOT be eligible if...** - Your cancer has spread beyond the cervix or to distant organs - You have received prior surgery, radiation, or chemotherapy for cervical cancer - You have autoimmune conditions that prevent immunotherapy Talk to your doctor to see if this trial is right for you.